^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Navelbine oral (vinorelbine tartrate oral)

    i
    Other names: VRL
    Associations

    News

    Trials
    Company:
    Pierre Fabre
    Drug class:
    Tubulin polymerization inhibitor
    Related drugs:
    Associations

    News

    Trials
    21d
    Levels of Circulating Tumor DNA as a Predictive Marker for Early Switch in Treatment for Patients With Metastatic (Stage IV) Breast Cancer (clinicaltrials.gov)
    P2, N=24, Active, not recruiting, University of Miami | Recruiting --> Active, not recruiting | N=500 --> 24
    Enrollment closed • Enrollment change • Circulating tumor DNA
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 negative
    |
    Lynparza (olaparib) • Ibrance (palbociclib) • everolimus • tamoxifen • Talzenna (talazoparib) • capecitabine • Piqray (alpelisib) • Verzenio (abemaciclib) • Kisqali (ribociclib) • fulvestrant • Halaven (eribulin mesylate) • Truqap (capivasertib) • letrozole • anastrozole • exemestane • Orserdu (elacestrant) • Navelbine oral (vinorelbine tartrate oral)
    1m
    Update on pediatric soft tissue sarcomas. (PubMed, Curr Opin Pediatr)
    Pediatric STS are rare and biologically heterogeneous. Genomic advances have refined risk stratification and uncovered therapeutic targets; further progress relies on international collaboration and trials.
    Review • Journal • PD(L)-1 Biomarker • IO biomarker
    |
    TP53 (Tumor protein P53) • FOXO1 (Forkhead box O1) • NTRK (Neurotrophic receptor tyrosine kinase) • MYOD1 (Myogenic Differentiation 1)
    |
    TP53 mutation • NTRK positive • NTRK fusion
    |
    Herceptin (trastuzumab) • Tecentriq (atezolizumab) • Vitrakvi (larotrectinib) • pazopanib • cyclophosphamide • Tazverik (tazemetostat) • Tecelra (afamitresgene autoleucel) • Navelbine oral (vinorelbine tartrate oral)
    2ms
    Evolutionary Therapy for Rhabdomyosarcoma (clinicaltrials.gov)
    P2, N=12, Active, not recruiting, H. Lee Moffitt Cancer Center and Research Institute | Recruiting --> Active, not recruiting | N=28 --> 12
    Enrollment closed • Enrollment change
    |
    FOXO1 (Forkhead box O1)
    |
    doxorubicin hydrochloride • cyclophosphamide • irinotecan • vincristine • vinorelbine tartrate • dactinomycin • Navelbine oral (vinorelbine tartrate oral)
    3ms
    A single-arm clinical study of subcutaneous injection of enolumab combined with oral vinorelbine as the first-line treatment for elderly patients with advanced non-small cell lung cancer (ChiCTR2500109581)
    P2, N=62, Not yet recruiting, The First Affiliated Hospital of Guangzhou Medical University; The First Affiliated Hospital of Guangzhou Medical University
    New P2 trial
    |
    EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase)
    |
    ALK mutation • EGFR negative
    |
    Navelbine oral (vinorelbine tartrate oral)
    5ms
    Trastuzumab + Alpelisib +/- Fulvestrant vs Trastuzumab + CT in Patients With PIK3CA Mutated Previously Treated HER2+ Advanced BrEasT Cancer (ALPHABET) (clinicaltrials.gov)
    P3, N=27, Active, not recruiting, Spanish Breast Cancer Research Group | Trial primary completion date: Jun 2025 --> Jun 2026 | Trial completion date: Jun 2025 --> Jun 2026
    Trial completion date • Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • PGR (Progesterone receptor)
    |
    ER positive • PIK3CA mutation
    |
    Herceptin (trastuzumab) • capecitabine • Piqray (alpelisib) • fulvestrant • Halaven (eribulin mesylate) • vinorelbine tartrate • Navelbine oral (vinorelbine tartrate oral)
    6ms
    SYSKY-2023-1016-01: Randomized, Open, Controlled, Multicenter Phase III Clinical Study of Fluzoparib in Combination With Apatinib Versus Investigator-Selected Chemotherapy for HRD-Positive/HER2-negative Advanced Breast Cancer (clinicaltrials.gov)
    P3, N=200, Recruiting, Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Not yet recruiting --> Recruiting
    Enrollment open
    |
    BRCA (Breast cancer early onset)
    |
    gemcitabine • paclitaxel • AiTan (rivoceranib) • capecitabine • Halaven (eribulin mesylate) • AiRuiYi (fluzoparib) • Navelbine oral (vinorelbine tartrate oral)
    6ms
    A single-arm, single-center, phase II clinical study of ivorximab combined with metrometric chemotherapy in the treatment of advanced or metastatic squamous NSCLC after failure of second-line or more systemic therapy (ChiCTR2500106870)
    P2, N=30, Not yet recruiting, Shandong First Medical University Affiliated Tumor Hospital; Shandong First Medical University Affiliated Tumor Hospital
    New P2 trial
    |
    Teysuno (gimeracil/oteracil/tegafur) • Navelbine oral (vinorelbine tartrate oral)
    6ms
    VINOREAL: To Describe How Well Vinorelbine Given Orally Works in Patients With a Breast Cancer After 2 Years of Treatment (clinicaltrials.gov)
    P=N/A, N=368, Recruiting, Pierre Fabre Medicament | Not yet recruiting --> Recruiting | Trial primary completion date: Sep 2026 --> Feb 2028
    Enrollment open • Trial primary completion date
    |
    Navelbine oral (vinorelbine tartrate oral)
    7ms
    Continuous Anlotinib Combined with Oral Vinorelbine has Shown Anti-Tumor Efficiency in Refractory HER2 Negative Advanced Breast Cancer. (PubMed, Breast Cancer (Dove Med Press))
    The most common grade 3-4 AEs that we observed were neutropenia (17.1%), leukopenia (9.8%) and diarrhea (9.8%). Continuous administration of anlotinib combined with oral vinorelbine demonstrates to be efficacious and well tolerated for refractory HER2 negative ABC.
    Journal
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 positive • HR positive • HER-2 negative • HR positive + HER-2 negative
    |
    Focus V (anlotinib) • Navelbine oral (vinorelbine tartrate oral)
    8ms
    IMMUNOLIFE2: Oral Pooled Fecal Microbiotherapy (MaaT033) Concomitant to Cemiplimab Versus Best Investigator's Choice in Patients With Resistance to Treatment Due to Antibiotics Uptake With Advanced Non-small Cell Lung Cancer (clinicaltrials.gov)
    P2, N=162, Not yet recruiting, Gustave Roussy, Cancer Campus, Grand Paris
    New P2 trial
    |
    Avastin (bevacizumab) • cisplatin • carboplatin • gemcitabine • paclitaxel • docetaxel • pemetrexed • Libtayo (cemiplimab-rwlc) • MaaT033 • Navelbine oral (vinorelbine tartrate oral)
    9ms
    Treatment of Newly Diagnosed Rhabdomyosarcoma Using Molecular Risk Stratification and Liposomal Irinotecan Based Therapy in Children With Intermediate and High Risk Disease (clinicaltrials.gov)
    P2, N=135, Recruiting, St. Jude Children's Research Hospital | Phase classification: P1/2 --> P2 | N=100 --> 135
    Phase classification • Enrollment change
    |
    TP53 (Tumor protein P53) • FOXO1 (Forkhead box O1) • MYOD1 (Myogenic Differentiation 1)
    |
    TP53 mutation
    |
    temozolomide • cyclophosphamide • vincristine • vinorelbine tartrate • dactinomycin • Onivyde (nanoliposomal irinotecan) • Navelbine oral (vinorelbine tartrate oral) • Neupogen (filgrastim)
    10ms
    Oral Vinorelbine or Capecitabine Combined With Trastuzumab as Adjuvant Treatment for Patients With Lymph Node Negative, HER-2 Positive and Small Tumor Size Breast Cancer (ORCHID) (clinicaltrials.gov)
    P2, N=178, Active, not recruiting, Fudan University | Unknown status --> Active, not recruiting | Trial completion date: May 2021 --> Jun 2027 | Trial primary completion date: May 2021 --> Jul 2025
    Enrollment closed • Trial completion date • Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 positive
    |
    Herceptin (trastuzumab) • capecitabine • Navelbine oral (vinorelbine tartrate oral)